Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Guns For Top-Three Pharmaceutical Seat In China

This article was originally published in PharmAsia News

Executive Summary

Greater China has been the fastest-growing region for Bayer HealthCare; its pharmaceutical business there increased 30 percent to achieve revenue of €1.8 billion in 2007 ($2.8 billion). The company attributes the success to its focus on OTC business. Generics, especially OTC drugs, will form the core of Bayer's growth in China after 2008 and it aims to be among the top three health care MNCs. However, some gaps need plugging: the firm has yet to launch in the country its top three blockbuster drugs, namely, Betaferon (interferon beta-1b), Yasmin (drospirenone/ethinyl estradiol) and Kogenate (recombinant clotting factor VIII). Bayer Schering Pharma plans to launch all its global heavyweights in China within three years and introduce over 20 new products within five years. (Click here for more - Chinese Language)

You may also be interested in...



Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

As COVID Vaccine Market Goes Private, US Government Can Still Help Firms Boost Sales

Pfizer and Moderna’s ‘endemic’ COVID vaccine market scenarios anticipate much higher booster rates than have been achieved so far, but performance for 2023 may be aided by the Biden Administration campaign to increase shots this winter.

Regeneron President Booed At Conference Over Comments Urging Focus On Innovation Before Access

Regeneron President George Yancopoulos got in a screaming match at Milken conference, arguing paying for cures is a secondary problem that should be tackled once such products are developed. He also talked about how he believes tech companies are helping to create some of America’s health crises.

Latest News
See All
UsernamePublicRestriction

Register

SC068979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel